Exogenous reproductive hormone use in breast cancer survivors and previvors.

Exogenous reproductive hormone use in breast cancer survivors and previvors. Nat Rev Clin Oncol. 2018 Jan 23;: Authors: Vaz-Luis I, Partridge AH Abstract Considerable controversy exists regarding the safety of elective exogenous hormonal exposure among breast cancer survivors and women at high risk of developing the disease (referred to herein as 'previvors'). We performed a qualitative analysis focused on four areas of potential exogenous exposure to hormones among previvors and survivors: hormonal contraception; systemic hormone-replacement therapy (HRT); localized HRT; and hormonal manipulation for fertility preservation or enhancement. Herein, we discuss the available data and present clinical recommendations regarding the safety of hormonal exposure for both previvors and survivors. We found these data to be hampered by small cohort sizes, heterogeneous patient populations, and limited study designs, highlighting a great need to conduct further research with the aim of enabling better-informed patient management. PMID: 29358778 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Nat Rev Clin Oncol Source Type: research

Related Links:

ConclusionThis study supports the use of a probably benign assessment of asymptomatic complicated cysts irrespective of age. The sensitivity for malignancy was 100% in our cohort.
Source: Academic Radiology - Category: Radiology Source Type: research
Mutations in DNA repair pathways, including breast-cancer susceptibility gene 1 (BRCA1) and breast-cancer susceptibility gene 2 (BRCA2) mutation carries, predispose women to an elevated lifetime risk for ovarian cancer (OC) and breast cancer (BC) (National Comprehensive Cancer Network Guidelines, 2018). While the role of bilateral risk-reducing mastectomy is still controversial, risk-reducing salpingo-oophorectomy (RRSO) represents nowadays the main effective prophylactic OC risk measure that should be proposed to BRCA carries, especially once childbearing is complete (National Comprehensive Cancer Network Guidelines, 2018...
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Source Type: research
Breast cancer is the most prevalent cancer in the U.S., affecting almost 85 of every 100,000 Americans, according to recent data from the World Health Organization’s International Agency for Research on Cancer (IARC). Around the globe, 627,000 people are projected to die from breast cancer this year alone. The silver lining is that with early detection and proper care, breast cancer is among the most treatable forms of the disease. In the U.S., breast cancer deaths dropped by 40% between 1989 and 2015, thanks to better screening and access to care — but a large body of research suggests that widespread adoption...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized breast cancer news Source Type: news
Our panel this morning discussed the issues surrounding how the WHI results were interpreted and communicated to women and their health care providers. We recognize that hormones are not appropriate for all women, and look forward to hosting a future panel that highlights alternatives. The speakers have a variety of backgrounds and experiences (and genders), and we aim to promote diversity of voices. This was not normal breakfast conversation. Today was a jolting – and disruptive – talk about what happens to women’s bodies when they age. (Who knew that if you’re menopausal and you don’t take y...
Source: Disruptive Women in Health Care - Category: Consumer Health News Authors: Tags: Uncategorized Source Type: blogs
Ever since a report by a U.S. study claimed in 2002 that it carried a significant risk of breast cancer and heart disease, most menopausal women remain scared of taking it.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
From time to time I have commented on the controversies over cancer screening. Most people assume that screening is an unqualified good, that early detection of cancer saves lives. Whenever some panel proposes recommending less screening, we hear screaming and yelling from advocates who claim they are trying to " ration " health care to save money at the expense of people's lives.In fact,as a bunch of Australians and a Minnesotan explain in BMJ, there are a few conditions called " cancer " that you are better off not treating, or perhaps treating very conservatively. These include what is called ductal ...
Source: Stayin' Alive - Category: American Health Source Type: blogs
AbstractMammographic density (MD) is a strong independent risk factor for breast cancer. It has been suggested that breast cancer is related to the exposure to circulating sex hormones. However, relations between MD and hormones have been inconsistent. In addition, such relations are mainly evaluated in Western populations. Therefore, we conducted a cross-sectional study in 396 cancer-free postmenopausal Korean women who had never used hormone replacement therapy. We assayed estradiol, testosterone, and sex hormone-binding globulin (SHBG) levels. We then calculated free testosterone (cFT) levels. Total and dense areas of d...
Source: Hormones and Cancer - Category: Cancer & Oncology Source Type: research
ConclusionsAsian HRT users had a higher risk of breast cancer than western HRT users. Both ET and EPT were significantly associated with the risk of all breast cancer histological types and ER-positive breast cancer.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionBreast density is an independent and significant risk factor for development of contralateral breast cancer. This risk factor should contribute to clinical decision making.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Currently, there is insufficient high-quality evidence to inform women considering HRT after treatment for endometrial cancer. The available evidence (both the single RCT and non-randomised evidence) does not suggest significant harm, if HRT is used after surgical treatment for early-stage endometrial cancer. There is no information available regarding use of HRT in higher-stage endometrial cancer (FIGO stage II and above). The use of HRT after endometrial cancer treatment should be individualised, taking account of the woman's symptoms and preferences, and the uncertainty of evidence for and against HRT use. ...
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tags: Cochrane Database Syst Rev Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Hormone Replacement Therapy | Hormones | Reproduction Medicine | Study | Women